Mesenchymal stem cell - derived extracellular vesicles modulate immune function in sepsis

Area of Science:

• Immunology
• Stem Cell Therapy
• Sepsis Pathophysiology

Background:

• Severe sepsis involves immune dysregulation, leading to high mortality.
• Current treatments lack effective biomarkers and immunomodulatory therapies.
• Extracellular vesicles from stem cells (iMSC-EVs) are a potential cell-free therapy for sepsis.

Purpose of the Study:

• To investigate the effects of iMSC-EVs on immune dysfunction in human sepsis.
• To identify biomarkers associated with sepsis mortality.
• To evaluate the therapeutic potential of iMSC-EVs in a sepsis patient cohort.

Main Methods:

• Prospective enrollment of 53 surgical sepsis patients.
• Analysis of 60-day mortality to define survivor and non-survivor groups.
• Quantification of cytokine profiles and assessment of peripheral blood mononuclear cell (PBMC) responses to LPS and iMSC-EVs.

Main Results:

• Elevated IL-10, MCP-1, and IL-10/TNF-α ratio predicted mortality in non-survivors.
• Non-survivors' PBMCs showed distinct cytokine responses.
• iMSC-EV treatment reduced inflammation, apoptosis, and modulated acute-phase markers in septic PBMCs.

Conclusions:

• Patient characteristics and cytokine profiles correlate with sepsis mortality and immunosuppression.
• iMSC-EVs demonstrate immunomodulatory and cytoprotective effects on septic PBMCs.
• iMSC-EVs hold promise as a cell-free therapeutic strategy for sepsis immune restoration.